Dextech Medical AB (XSAT:DEX)
Sweden flag Sweden · Delayed Price · Currency is SEK
7.40
-0.10 (-1.33%)
At close: Aug 15, 2025

Dextech Medical AB Company Description

Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer.

Its principal product candidate is OsteoDex that has completed phase IIb clinical trial for the treatment of skeletal metastases in castration resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma.

The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, to treat acromegaly, neuroendocrine tumors, and palliative treatment for advanced prostate cancer; and PSMA-binding conjugates for the target-specific treatment of mCRPC that overexpresses prostate specific membrane antigen (PSMA).

In addition, the company offers GuaDex (formarly CatDex), a technology platform and a charge-modified dextran molecule with tumor-toxic properties used for medication development.

Dextech Medical AB was incorporated in 2004 and is based in Uppsala, Sweden.

Dextech Medical AB
CountrySweden
Founded2004
IndustryBiological Products, Except Diagnostic Substances
Employees1
CEOAnders Holmberg

Contact Details

Address:
Dag HammarskjOelds VAeg 34A
Uppsala, 752 37
Sweden
Phone46 7 07 10 47 88
Websitedextechmedical.com

Stock Details

Ticker SymbolDEX
ExchangeSpotlight Stock Market
Fiscal YearJuly - June
Reporting CurrencySEK
SIC Code2836

Key Executives

NamePosition
Anders HolmbergChief Executive Officer
Gösta LundgrenChief Financial Officer
Gösta LundgrenHead of Investor Relations